BioCentury
ARTICLE | Strategy

Building Bioverativ

How Biogen spinout Bioverativ plans to survive as stand-alone company

February 11, 2017 2:38 AM UTC
In November, said seven of the first nine patients treated in a trial of showed “consistent and sustained” Factor IX activity levels. Additionally, four patients stopped prophylactic factor replacement therapy without breakthrough bleeding.

Biogen Inc.’s newly minted hematology spinout Bioverativ Inc. will have at least three years to build market share for its hemophilia therapies and flesh out its pipeline before gene therapies potentially hit the market. Given the level of competition, the newco has its work cut out for it, but CEO John Cox said it has the resources it needs.

Bioverativ launched Feb. 2 with a NASDAQ listing and Biogen’s hematology assets, which include two marketed long-acting clotting factor replacements and a portfolio of preclinical candidates. ...